PE Tech Report


Like this article?

Sign up to our free newsletter

Alex Therapeutics raises EUR3.5m in oversubscribed financing round from VC investors

Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics today announces it has secured EUR3.5 million in a funding round led by European life science venture fund Hadean Ventures and joined by Scale Capital and Bonit Capital.

Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies seeking to develop and launch DTx solutions. These digital health products are validated in clinical trials and prescribed by a doctor, similar to traditional therapeutics. This funding round will be used to accelerate Alex’s growth in Europe and the US and to develop novel DTx products alongside both new and existing partners, including Pfizer.

The round was led by Hadean Ventures, a European specialist life science venture fund, with participation from Scale Capital and Bonit Capital, the Leksell (founder of medical device company Elekta) family office. The new investors provide cross-disciplinary expertise in successfully developing medical devices and scaling global B2B tech platforms. Existing investors, the King (Candy Crush) founders through their fund Sweet Studio, also participated in the round.

Like this article? Sign up to our free newsletter